[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Braile Biomedica Ind. Com. e Repr. Ltda.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":66},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,39],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100560153","clinical-performance-of-the-vesto-vascular-stent-for-treatment-of-iliac-peripheral-obstructive-arterial-disease-100560153",false,"NCT06573437","Clinical Performance of the VESTO® Vascular Stent for Treatment of Iliac Peripheral Obstructive Arterial Disease","Clinical Performance of the VESTO® Vascular Stent for Treatment of Iliac Peripheral Obstructive Arterial Disease - Post Market Clinical Trial Iliac Stent Trial","VESTO-ILIAC","Inclusion Criteria:\n\n1. 18 years of age or older;\n2. TASC-II aortoiliac lesion classification of modified class A, B, C, or D;\n3. Rutherford classification score of 2 to 5;\n4. Access site compatibility with the device delivery system;\n5. Compliance with the device's instructions for use (IFU);\n6. Patient availability for appropriate follow-up times for the duration of the study;\n7. Patient informed about the nature of the study, agreeing to its provisions, and signing the informed consent form.\n\nExclusion Criteria:\n\n1. Known hypersensitivity to heparin, contrast media, or stent components;\n2. Patient with blood dyscrasia;\n3. Pregnant or breastfeeding women;\n4. Patient currently participating in an investigational drug or device study;\n5. Patient undergoing chemotherapy or radiation therapy;\n6. Patient with a stent or graft located in the target limb;\n7. Patient who underwent angioplasty or bypass surgery within 30 days prior to inclusion in this study;\n8. Patient with a life expectancy of less than 12 months;\n9. Inability to undergo dual antiplatelet therapy (DAPT)","ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","OBSERVATIONAL","This study will validate the efficacy and safety of the VESTO® Vascular Stent for treating patients with iliac peripheral arterial obstructive disease in a post-market clinical trial",[25],"Peripheral Arterial Disease","RECRUITING","2025-03-21",{"date":29,"type":30},"2025-03-26","ACTUAL",{"date":32,"type":30},"2024-06-21",{"date":34,"type":21},"2026-08",{"name":36,"class":37},"Braile Biomedica Ind. Com. e Repr. Ltda.","INDUSTRY",6,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":48,"conditions":49,"keywords":51,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},"100536877","post-market-clinical-trial-of-the-dominus-stent-graft-100536877","NCT06270537","Post-market Clinical Trial of the Dominus® Stent-Graft","Multicenter Study Collecting Post-market Clinical Data on the Dominus® Stent-Graft for Treating Thoracic Aortic Diseases","DominusPMCF","Inclusion Criteria:\n\n1. 18 years of age or older;\n2. Patients treated with the Dominus® Stent-Graft Endoprosthesis in accordance with its Instructions for Use;\n3. Patient available for appropriate follow-up times for the study duration;\n4. Informed patient about the nature of the study, agreeing to its provisions, and signing the informed consent.\n\nExclusion Criteria:\n\n1. Patient currently participating in another clinical study of drug or medical device;\n2. Life expectancy less than 12 months.",{"count":20,"type":21},"Real-world clinical trial evidence post-market, evaluating the safety and efficacy of the Dominus® StentGraft Endoprosthesis in treating thoracic aortic diseases, following the Instructions for Use",[50],"Thoracic Aortic Dissection",[52,53,54,55,56],"Aneurysm","Acute Aortic Syndrome","Aortic Dissection","Aortic Diseases","Cardiovascular Diseases","2024-08-21",{"date":59,"type":30},"2024-08-22",{"date":61,"type":30},"2023-10-24",{"date":63,"type":21},"2029-02-28",{"name":36,"class":37},3,""]